IDEXX Laboratories (IDXX) announced that the Company’s Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company’s common stock. Repurchases may be made at management’s discretion from time to time in the open market or in negotiated transactions. These shares are in addition to the 1.3 M shares remaining under the Company’s ongoing share repurchase program as of December 3 pursuant to previous Board authorizations. The share repurchase program has no specified expiration date and may be suspended or discontinued at any time.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Tesla upgraded, Autodesk initiated: Wall Street’s top analyst calls
- Idexx Laboratories initiated with an Outperform at Leerink
- IDEXX Laboratories Announces CFO Transition Plan
- Idexx Laboratories backs FY24 EPS view $10.37-$10.53, consensus $10.73
- Idexx Laboratories CFO Brian McKeon to retire, Andrew Emerson to succeed